ethyl 4,7-dichloro-6-fluoroquinoline-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 4,7-dichloro-6-fluoroquinoline-3-carboxylate
• 英文别名: 4,7-dichloro-6-fluoro-3-ethoxycarbonylquinoline；ethyl 6-fluoro-4,7-dichloro-quinoline-3-carboxylate
• 化学式: C₁₂H₈Cl₂FNO₂
• 分子量: 288.105
• InChiKey: VTLWFGZACOOWFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4,7-dichloro-6-fluoroquinoline-3-carboxylate 生成 ethyl 7-chloro-4-(4-chlorophenyl)sulfanyl-6-fluoro-3-quinolinecarboxylate
  参考文献：
  名称：

  Quinoline compounds

  摘要：

  一种通过将细胞暴露于公式##STR1##的化合物或其药学上可接受的盐中，抑制细胞增殖或分化的方法。其中，Q从NH和S组成的群体中选择，n为0或1；R.sub.1-9分别从卤、三卤甲基、烷基、硝基、羟基、烷氧基、硫氧基、磺酰基、酰胺、磺酰胺、羧酰胺、氨基和氢中独立选择。还提供了结构式##STR2##的化合物。

  公开号：

  US05650415A1
• 作为产物：
  描述：

  二乙基[[(3-氯-4-氟苯基)氨基]亚甲基]丙二酸酯 在 三氯氧磷 作用下， 以 二苯醚 为溶剂， 反应 1.75h， 生成 ethyl 4,7-dichloro-6-fluoroquinoline-3-carboxylate
  参考文献：
  名称：

  新型3-（喹啉-4-基氨基）苯磺酰胺作为碳酸酐酶同工型I和II抑制剂的合成及生物学评价

  摘要：

  抽象的 碳酸酐酶（CAs，EC 4.2.1.1）是涉及多种生物过程的关键金属酶。我们报告了合成和生物学评估的新系列的苯磺酰胺结合未/取代的乙基喹啉-3-羧酸酯部分。新合成的化合物在体外评估为胞质人（h）亚型hCA I和II的抑制剂。此处报道的喹啉在不同程度上均抑制了hCA I和II亚型：h CA I在0.966–9.091μM范围内被K I s抑制，而hCA II在0.083–3.594μM范围内被抑制。主7-氯-6- flouro取代sulphfonamide衍生物6E（ķ我 = 0.083μM）被证明是抑制hCA II活性最强的喹啉，而其次磺酰胺类似物未能抑制hCA II直至10μM，从而证实了主要的磺酰胺类作为锌结合基团的关键作用。 CA抑制活性。

  DOI：

  10.1080/14756366.2019.1652282

文献信息

• THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES
  申请人：Kaplan Alan P.

  公开号：US20080306049A1

  公开（公告）日：2008-12-11

  The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA A receptor and modulating GABA A , and use of the compound of formula I for the treatment of GABA A receptor associated disorders. The general structure of formula I is shown below and can exist in tautomeric forms: The invention further provides a method of modulation of one or more GABA A subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).

  这项发明提供了一种新颖的化学系列，其化学式为I，以及用于结合到GABA A 受体的苯二氮卓类位点并调节GABA A 的使用方法，以及用于治疗与GABA A 受体相关疾病的化合物的使用。化学式I的一般结构如下所示，并且可以存在互变异构体形式： 该发明还提供了一种在动物中调节一个或多个GABA A 亚型的方法，包括向动物投与化学式(I)化合物的有效量。
• Quinoline Compounds, Intermediates, Preparation Methods and Uses Thereof
  申请人：Cai Zhengyan

  公开号：US20110046379A1

  公开（公告）日：2011-02-24

  A kind of quinoline compounds as formula A, pharmaceutical accepted solvates, optical isomers or polymorphisms thereof. The intermediates of formula D. in which, R 1 , R 2 and R 3 is independently H, halo or the subustitents of formula H, in which, R is H, halo, C 1 ˜C 4 alkyl, C 1 ˜C 4 alkoxyl. The preparation methods and the uses for the manufacture of a medicament of inhibiting the HMG CoA reductase and treating the diseases relating to the high blood fat. Compared with the fluvastatin, rosuvatatin, pitavastatin disclosed in the prior arts, present quinoline compounds have better activity of inhibiting HMG CoA reductase. Present quinoline compounds can be used for treating the diseases relating to the high blood fat.

  一种喹啉类化合物，其化学式为A，药物可接受的溶剂化合物、光学异构体或其多晶形态。公式D的中间体。其中，R1、R2和R3独立地为H、卤素或公式H的取代基，其中，R为H、卤素、C1~C4烷基、C1~C4烷氧基。制备方法及用于制造抑制HMG CoA还原酶和治疗与高血脂相关疾病的药物的用途。与先前公开的氟伐他汀、罗伐他汀、匹伐他汀相比，目前的喹啉类化合物具有更好的抑制HMG CoA还原酶活性。目前的喹啉类化合物可用于治疗与高血脂相关的疾病。
• Synthesis and HMG CoA reductase inhibition of 4-thiophenyl quinolines as potential hypocholesterolemic agents
  作者：Zhengyan Cai、Weicheng Zhou、Lixin Sun

  DOI：10.1016/j.bmc.2007.08.044

  日期：2007.12

  8-trisubstituted-4-chloro-quinoline-3-carboxylates by several reactions and evaluated for their ability to inhibit the rat HMG CoA reductase in vitro. It was found that substitution with a variety of thiophenyl groups at position 4 in quinoline resulted in retention or enhancement of the inhibition and the preferable groups were 4-isopropyl-thiophenyl and 3-methoxy-thiophenyl. (4R,6S)-6-[(E)-2-(6,7,8-trifluoro-4

  由6,7,8-三取代-4-氯喹啉-3-羧酸乙酯经数个反应合成了一系列新颖的基于4-硫代苯基喹啉的甲羟戊酸内酯衍生物，并评估了它们在体外抑制大鼠HMG CoA还原酶的能力。 。发现在喹啉的4位上被各种硫代苯基取代会导致抑制作用的保持或增强，优选的基团是4-异丙基-硫代苯基和3-甲氧基-硫代苯基。（4R，6S）-6-[（E）-2-（6,7,8-三氟-4-异丙基硫代苯基-喹啉-3-基）-乙烯基]-3,4,5,6-四氢-4-羟基-2H-吡喃-2-酮（A16）和（4R，6S）-6-[（E）-2-（6-氟-4,7-二-（3-甲氧基-硫代苯基）-喹啉-3 -基）-乙烯基] -3,4，5，
• Synthesis and biological evaluation of small molecule modulators of CDK8/Cyclin C complex with phenylaminoquinoline scaffold
  作者：Mohammad M. Al-Sanea

  DOI：10.7717/peerj.8649

  日期：——

  CDK8/CycC complex has kinase activity towards the carboxyterminal domain of RNA polymerase II, and contributes to the regulation of transcription via association with the mediator complex. Different human malignancies, mainly colorectal and gastric cancers, were produced as a result of overexpression of CDK8/CycC in the mediator complex. Therefore, CDK8/CycC complex represents as a cancer oncogene and it has become a potential target for developing CDK8/CycC modulators.

  A series of nine 4-phenylaminoquinoline scaffold-based compounds 5a-i was synthesized, and biologically evaluated as potential CDK8/CycC complex inhibitors.

  The scaffold substituent effects on the intrinsic inhibitory activity toward CDK8/CycC complex are addressed trying to present a novel outlook of CDK8/CycC Complex inhibitors with 4-phenylaminoquinoline scaffold in cancer therapy. The secondary benzenesulfonamide analogues proved to be the most potent compounds in suppressing CDK8/CycC enzyme, whereas, their primary benzenesulfonamide analogues showed inferior activity. Moreover, the benzene reversed sulfonamide analogues were totally inactive.

  The titled scaffold showed promising inhibitory activity data and there is a crucial role of un/substituted sulfonamido group for CDK8/CycC complex inhibitory activity. Compound 5d showed submicromolar potency against CDK8/CycC (IC₅₀ = 0.639 µM) and it can be used for further investigations and to design another larger library of phenylaminoquinoline scaffold-based analogues in order to establish detailed SARs.

  CDK8/CycC复合物具有对RNA聚合酶II羧基末端结构的激酶活性，并通过与中介体复合物的结合参与转录调控。过表达CDK8/CycC在中介体复合物中是导致不同人类恶性肿瘤，主要是结肠直肠癌和胃癌的原因。因此，CDK8/CycC复合物代表了一种癌症致癌基因，已成为开发CDK8/CycC调节剂的潜在靶点。

  合成了一系列基于9个4-苯胺基喹啉支架的化合物5a-i，并在生物学上评估其作为潜在的CDK8/CycC复合物抑制剂。

  探讨了支架取代基对CDK8/CycC复合物固有抑制活性的影响，试图提供使用4-苯胺基喹啉支架的CDK8/CycC复合物抑制剂在癌症治疗中的新视角。次级苯磺酰胺类似物被证明是抑制CDK8/CycC酶最有效的化合物，而它们的主要苯磺酰胺类似物表现出较差的活性。此外，苯环反转磺酰胺类似物完全没有活性。

  这个支架显示了有前途的抑制活性数据，并且未/取代磺酰胺基团对于CDK8/CycC复合物的抑制活性起着至关重要的作用。化合物5d对CDK8/CycC表现出亚微米级的抑制活性（IC50 = 0.639 µM），可以用于进一步的研究，并设计另一个更大的基于苯胺基喹啉支架的类似物库，以建立详细的SAR。

• Therapeutic pyrazoloquinoline derivatives
  申请人：Helicon Therapeutics, Inc.

  公开号：US07872002B2

  公开（公告）日：2011-01-18

  The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and modulating GABAA, and use of the compound of formula I for the treatment of GABAA receptor associated disorders. The general structure of formula I is shown below and can exist in tautomeric forms: The invention further provides a method of modulation of one or more GABAA subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).

  本发明提供了一种新的化学系列I的公式，以及其使用方法，用于结合GABAA受体的苯二氮平位点和调节GABAA，以及使用公式I的化合物治疗GABAA受体相关疾病。公式I的一般结构如下所示，并且可以存在互变异构体：本发明还提供了一种在动物中调节一个或多个GABAA亚型的方法，包括向动物投与公式（I）的化合物的有效量。